AndreaBozzo/ceres-open-data-index huggingface dataset:
State Panel Discussion Cloud Computing

The Children's Bureau hosted a state panel from the previous cloud computing webinar held on September 5, 2018 for a follow-up discussion. The previous webinar on implementing a cloud computing strategy for child welfare information systems received very positive feedback and while it provided valuable information, there was insufficient time to fully explore all the issues.

Part 2 of this panel discussion included:

The returning speakers for this panel were:

Arizona

Florida

Maryland

Metadata-only record linking to the original dataset. Open original dataset below.
Long terminal repeat retrotransposons of

A new data-mining program, LTR_STRUC, was used to mine the GenBank rice (Oryza sativa) database as well as the more extensive Monsanto rice dataset for long terminal repeat retrotransposons. Each of the major clades of rice LTR retrotransposons is more closely related to elements present in other species than to the other clades of rice elements, suggesting that horizontal transfer may have occurred.
National Household Survey on Drug Abuse (NHSDA-1999)

<p>The National Household Survey on Drug Abuse (NHSDA) series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions include age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covers substance abuse treatment history and perceived need for treatment, and includes questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. Respondents are also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous NHSDA administrations were retained in the 1999 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, gang involvement, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving behavior and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. Demographic data include sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.</p>
New immunosuppressive drugs in heart transplantation

Only a few randomized clinical trials have been performed so far in heart transplant recipients, mainly because of the relatively small number of heart transplants performed worldwide each year. The main focus of the few controlled trials that have been completed has been the prevention and treatment of heart allograft rejection. In the area of pharmacologic immunosuppression, both biological agents and drugs have been the subject of investigation. Among the biological agents, chimeric monoclonal antibodies directed against the interleukin (IL)-2 receptor, which have been found to be safe and effective in renal transplant recipients, are now undergoing the test of controlled trials in heart transplant recipients. Immunosuppressive drugs that have been studied in controlled trials include calcineurin inhibitors (such as the microemulsion formulation of cyclosporine and tacrolimus) and inhibitors of purine synthesis, such as mycophenolate mofetil. Non-pharmacologic prophylactic immunosuppression with photopheresis has also been tested in a prospective, multicenter, randomized trial. New immunosuppressive regimens, such as mycophenolate mofetil combined with a monoclonal antibody against the IL-2 receptor, are being tested with the aim to reduce or eliminate calcineurin inhibitors or corticosteroids. Although clinical approaches to the induction of tolerance have undergone preliminary clinical evaluation, the ability to induce tolerance to an allograft in humans remains an elusive goal.
Hospital Cost Report Audited Data: 2016

This version of the Institutional Cost Report (ICR) has been audited by a Certified Public Accounting Firm. The ICR is a uniform report completed by New York State hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm
Avacopan

Tavneos (avacopan) is an oral prescription capsule containing 10 mg of avacopan, manufactured by ChemoCentryx, Inc. It acts as a complement 5a receptor antagonist and cytochrome P450 3A4 inhibitor, approved by the FDA in October 2021 for treating certain inflammatory conditions. Available in bottles of 30 or 180 capsules. This information was generated using AI and is provided for informational and research purposes only.
Vitamin D receptor initiation codon polymorphism influences genetic susceptibility to type 1 diabetes mellitus in the Japanese population

Background
          Vitamin D has been shown to exert manifold immunomodulatory effects. Type 1 diabetes mellitus (T1DM) is regarded to be immune-mediated and vitamin D prevents the development of diabetes in the NOD mouse. We studied the association between T1DM and the initiation codon polymorphism in exon 2 of the vitamin D receptor gene in a Japanese population. We also investigated associations between the vitamin D receptor polymorphism and GAD65-antibody (Ab) positivity. We carried out polymerase chain reaction-restriction fragment length polymorphism analysis in 110 Japanese T1DM patients and 250 control subjects. GAD65 antibodies were assessed in 78 patients with T1DM.
        
        
          Results
          We found a significantly higher prevalence of the F allele / the FF genotype in the patients compared to the controls (P = 0.0069 and P = 0.014, respectively). Genotype and allele frequencies differed significantly between GAD65-Ab-positive patients and controls (P = 0.017 and P = 0.012, respectively), but neither between GAD65-Ab-negative patients and controls (P = 0.68 and P = 0.66, respectively) nor between GAD65-Ab-positive and -negative patients (P = 0.19 and P = 0.16, respectively).
        
        
          Conclusions
          Our findings suggest that the vitamin D receptor initiation codon polymorphism influences genetic susceptibility to T1DM among the Japanese. This polymorphism is also associated with GAD65-Ab-positive T1DM, although the absence of a significant difference between GAD65-Ab-negative patients and controls might be simply due to the small sample size of patients tested for GAD65 antibodies.
Complications and Deaths - Hospital

Complications and deaths - provider data. This data set includes provider-level data for the hip/knee complication measure, the CMS Patient Safety Indicators, and 30-day death rates. NOTICE: Data from the 1st and 2nd quarters of 2020 are not being reported due to the impact of the COVID-19 pandemic. For more information, please reference https://qualitynet.cms.gov/files/5fb838aef61c410025a64709?filename=2020-111-IP.pdf.
Clostridioides difficile infections (CDI) in California Hospitals

California Health and Safety Code section 1288.55(a)(1) requires general acute care hospitals to report all cases of Clostridioides difficile infections (CDI) identified in their facilities to the California Department of Public Health (CDPH). CDI data are submitted by hospitals to the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN). 

CDPH downloads California hospital CDI data from NHSN and analyzes the data to describe prevention progress in an annual public report of healthcare-associated infections CDPH publishes annual CDI data reported by each California hospital in the datasets below. 

The following datasets include the number of CDI reported by each California hospital in the specified reporting year. Beginning in 2016 for each California hospital, the annual CDI dataset includes the number of CDI that were predicted to occur in each hospital based on its specific facility-level characteristics. The observed (reported) number of CDI are then compared to the predicted number of CDI in a ratio called the Standardized Infection Ratio or SIR. The SIR is a metric that summarizes an individual hospital’s CDI prevention progress compared with the national baseline and California state-specific prevention goals. 

Detailed information about the variables included in each dataset are described in the accompanying data dictionaries for the year of interest.

For more information about the SIR and NHSN’s statistical models that are used to calculate the predicted number of CDI for each hospital, please review “NHSN’s Guide to the SIR”: https://www.cdc.gov/nhsn/ps-analysis-resources/index.html 

For general information about NHSN, surveillance definitions, and reporting requirements for CDI, please visit: https://www.cdc.gov/nhsn/index.html 

To link the CDPH facility IDs with those from other Departments, including HCAI, please reference the "Licensed Facility Cross-Walk" Open Data table at: https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk.

For information about healthcare-associated infection prevention progress in California hospitals and statewide prevention goals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AnnualHAIReports.aspx
Compound 528609: Butanamide, N-tert.-butyl-3-methyl

Chemical compound data from PubChem database. IUPAC Name: N-tert-butyl-3-methylbutanamide. Molecular Formula: C9H19NO. Molecular Weight: 157.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401042-T1: [Translated] METHOD AND DEVICE FOR EXTERNAL CARDIAC STABILIZATION

The present disclosure is directed to an external cardiac basal annuloplasty system (ECBAS or BACE-System: basal annuloplasty of the cardia externally) and methods for treatment of regurgitation of mitral and tricuspid valves. The BACE-System provides the ability to correct leakage of regurgitation of the valves with or without the use of cardiopulmonary bypass, particularly when the condition is related to dilation of the base of the heart. This ECBAS invention can be applied to the base of the heart epicardially, either to prevent further dilation or to actively reduce the size of the base of the heart.
New York State Statewide  COVID-19 Reinfection Data (Archived)

<b>Note: This dataset is no longer being updated as of September 1, 2023.</b>
This dataset reports the number of reinfections in New York State since January 2021. A reinfection is when a person becomes infected with COVID and later becomes infected again. A person is considered a reinfection if they test positive again 90 days or more after their first positive test. The goal of this dataset is to provide users timely information about the trends in reinfections in New York State. This dataset is created by the New York State Department of Health from data reported to Electronica Clinical Laboratory Reporting System (ECLRS).
Exposure to Substance Use Prevention Messages among Adolescents

The percentages of adolescents who were exposed to drug or alcohol use prevention messages in the past year by talking with their parents, through the media, or through school sources were generally lower in 2015 than in most years between 2002 and 2012 and were comparable with 2013 and 2014. In 2015, about 3 out of 4 adolescents aged 12 to 17 were exposed to substance use prevention messages in the media or at school, and about 1 out of 2 adolescents talked with their parents about substance use.
Applied pressure alters circulating hormone levels and biomarkers of peripheral vascular, sensorineural dysfunction

Workers that regularly use vibrating hand tools as part of their job are at risk of developing hand-arm vibration syndrome (HAVS).  HAVS is characterized by cold-induced vasospasms that result in blanching of the fingers and hands, loss of sensation, pain, and reductions in manual dexterity, all of which can affect a worker’s ability to perform their job and their quality of life.  Vibration exposure significantly contributes to the development of these symptoms by increasing the stress and strain within exposed tissues, which in turn can affect functioning of blood vessels, nerves and sensory receptors in those tissues.
Compound 526852: 2,3-Dimethyl-4-isopropyl-1-cyclopentanone

Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethyl-4-propan-2-ylcyclopentan-1-one. Molecular Formula: C10H18O. Molecular Weight: 154.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399589-T1: [Translated] LIQUID MIXING DEVICE

A mixer apparatus for use with a vessel centered about a longitudinal axis is disclosed. The mixer has a tubular blade which: defines a central head axis; has a first end and a second end spaced from the first end along the head axis; and tapers from the first end to the second end. The outer surface of the blade and the second end define an inside blade diameter "ID" and the outer surface of the blade and the first end define an outside blade diameter "OD". The blade is positioned within and coaxial to the vessel. A scotch yoke, operatively connected to the blade by a shaft, effects reciprocating longitudinal movement of the blade through a stroke "S", with a duration "T" for each stroke, wherein 175≲0.36 xOD<SUP>2</SUP>/ID<SUP>2</SUP>xS/T≲ 250 when OD, ID and S are expressed in inches, and T is expressed in minutes.
CDC STATE System E-Cigarette Legislation - Smokefree Indoor Air Summary

1995-2024. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation – Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air that apply to use of e-cigarettes in private worksites, restaurants, and bars.
Compound 527492: Kessanyl acetate

Chemical compound data from PubChem database. IUPAC Name: (1,5,9,9-tetramethyl-10-oxatricyclo[6.2.2.02,6]dodecan-12-yl) acetate. Molecular Formula: C17H28O3. Molecular Weight: 280.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1P. Hemolytic uremic syndrome post-diarrheal to Hepatitis B, acute

NNDSS - TABLE 1P. Hemolytic uremic syndrome post-diarrheal to Hepatitis B, acute - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
If You Build It They Will Come: Lessons Learned Through the Implementation of Text and Chat Services for Youth

The Childhelp National Child Abuse Hotline implemented text and chat services in 2019 in order to connect with youth at risk of and experiencing child abuse and neglect. This webinar will give a broad overview of the complex nature of providing information, education, and emotional support through written communication. Key considerations and recommendations for offering text and chat-based services will be shared based on the findings of the 5-year project.

This is the first of a three part webinar series. The second webinar takes a deeper dive in to the quantitative aspect of text, chat based services, including pre, and post survey questions, data collection, and understanding help seeker demographics and needs. It also addresses vicarious trauma and vicarious resilience of the front line worker.

The third webinar provides an overview of the qualitative research that led to an evidence-informed practice model in the setting of a victim service hotline communicating through text and chat modalities. It discusses continuous quality improvement initiatives, implementing a supportive supervision model and implications of advancing technology such as AI.

Audio Description Version

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526782: 8-Hydroxy-nonadecanoic, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 8-[tert-butyl(dimethyl)silyl]oxynonadecanoate. Molecular Formula: C26H54O3Si. Molecular Weight: 442.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Title IV-E Prevention Program Data Submission Fall 2022 Webinar

On November 1, 2022, the Children’s Bureau hosted a webinar on Title IV-E Program Data Submission which included a review of the data quality rules, provided clarity on some of the data elements, and reviewed the commonly observed errors in the first submission. The Webinar and Presentation slides may be accessed through the links below.

Descriptive Audio Version

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400222-T1: [Translated] SURGICAL INSTRUMENTS FOR DELIVERING MEDICINAL PRODUCTS

A medical agent dispensing system can be provided that may be structured for use with a surgical severing/stapling instrument (10) that is designed for severing and stapling tissue. The dispensing system may include at least one storage reservoir (92,94) structured for storing at least a component of a medical agent; a gear pump casing (72) in communication with the storage reservoir; a screw pump auger (76) positioned within the gear pump casing capable of rotational manipulation to move the medical agent through the gear pump casing; and, at least one agent tube (78,80) in communication with the gear pump casing. The agent tube may be structured for communication with at least one agent port (82,84,86) formed in a staple cartridge of the surgical instrument for dispensing the medical agent therethrough.
2019-2020 National Survey on Drug Use and Health: Model-Based Prevalence Estimates (50 States and the District of Columbia)

State estimates for these years are no longer available due to methodological concerns with combining 2019 and 2020 data. We apologize for any inconvenience or confusion this may causeBecause of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the two years could be misleading.For more detail on this decision, see the 2019-2020state data page.
Dexmedetomidine hydrochloride

Dexmedetomidine Hydrochloride is an injectable prescription drug used intravenously for sedation and anesthesia in medical settings, such as intensive care. It acts as a central alpha-2 adrenergic agonist to provide calming effects. Available in strengths like 200 mcg per 50 mL bag, it's a generic product from Baxter Healthcare Company. This information was generated using AI and is provided for informational and research purposes only.
Compound 527993: Propanoic acid, 2,2-dichloro-, heptyl ester

Chemical compound data from PubChem database. IUPAC Name: heptyl 2,2-dichloropropanoate. Molecular Formula: C10H18Cl2O2. Molecular Weight: 241.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.